BiotechTube

MN-166 (50 mg) First + Placebo First

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Abuse

Conditions

Opioid Abuse, Opioid Dependence

Trial Timeline

Nov 1, 2012 → May 1, 2017

NCT ID
NCT01740414

About MN-166 (50 mg) First + Placebo First

MN-166 (50 mg) First + Placebo First is a phase 2 stage product being developed by MediciNova for Opioid Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT01740414. Target conditions include Opioid Abuse, Opioid Dependence.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01740414Phase 2Completed

Competing Products

20 competing products in Opioid Abuse

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + NaloxegolAstraZenecaPhase 1
33
NKTR-118 + Usual careAstraZenecaPhase 3
77

Other Products from MediciNova

MN-166 + placeboPhase 2/3
57
Ibudilast + Placebo oral capsulePhase 2
44
MN-001 + PlaceboPhase 2
44
Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3Phase 2
44
Placebo (for MN-166) + MN-166 + riluzolePhase 2
44